South Korean biotechnology company
South Korean biotechnology company
Peru’s Digemid has approved South Korean regenerative medicine company L&C Bio’s Re2O, an injectable based on human skin extracellular matrix, for commercialisation; the company plans to use Peru as a …
You must be logged in to post a comment.